


MB-07811

Cat. No.:	HY-111288
CAS No.:	852948-13-1
Molecular Formula:	C ₂₈ H ₃₂ ClO ₅ P
Molecular Weight:	514.98
Target:	Thyroid Hormone Receptor
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	MB-07811 (VK-2809) is an orally active HepDirect prodrug of MB07344, a liver-targeted thyroid hormone receptor-β agonist ^[1] . MB-07811 has cholesterol and triglycerides lowering activity ^[2] .	
IC₅₀ & Target	Thyroid hormone receptor-β ^[2]	
In Vitro	MB-07811 is potential for liver targeting with a low affinity for thyroid hormone receptors (TRβ K _i = 14.6 ± 0.5 μM; TRα K _i = 12.5 ± 0.6 μM) ^[2] .	
In Vivo	MB-07811 (0.3-30 mg/kg; orally once daily for 14 days) reduces cholesterol and triglycerides in diet-induced obese mice ^[2] .	
	Animal Model:	4-week-old male C57BL/6 mice (diet-induced obese (DIO) mice) ^[2]
	Dosage:	0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg
	Administration:	Orally once daily; 14 days
	Result:	Reduced total plasma cholesterol, and reduced plasma triglycerides (40%) at the highest doses.

REFERENCES

[1]. Cable EE, et al. Reduction of hepatic steatosis in rats and mice after treatment with aliver-targeted thyroidhormone receptor agonist. *Hepatology*. 2009 Feb;49(2):407-17.

[2]. Erion MD, et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. *Proc Natl Acad Sci U S A*. 2007 Sep 25;104(39):15490-5.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA